S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
A One Stop Shop for Everything Futures Trading (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
A One Stop Shop for Everything Futures Trading (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
A One Stop Shop for Everything Futures Trading (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
A One Stop Shop for Everything Futures Trading (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
A One Stop Shop for Everything Futures Trading (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
A One Stop Shop for Everything Futures Trading (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
A One Stop Shop for Everything Futures Trading (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
A One Stop Shop for Everything Futures Trading (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
NASDAQ:ADMA

ADMA Biologics - ADMA Stock Forecast, Price & News

$2.43
+0.17 (+7.52%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.28
$2.48
50-Day Range
$2.03
$2.86
52-Week Range
$1.01
$2.92
Volume
2.99 million shs
Average Volume
3.62 million shs
Market Capitalization
$477.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.13

ADMA Biologics MarketRank™ Forecast

Analyst Rating
Buy
3.25 Rating Score
Upside/​Downside
69.8% Upside
$4.13 Price Target
Short Interest
Bearish
13.24% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.41mentions of ADMA Biologics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.31) to ($0.20) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

626th out of 1,095 stocks

Biological Products, Except Diagnostic Industry

102nd out of 171 stocks

ADMA stock logo

About ADMA Biologics (NASDAQ:ADMA) Stock

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Receive ADMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter.

ADMA Stock News Headlines

ADMA Biologics, Inc. (ADMA)
Why ADMA Biologics Stock Triumphed on Thursday
ADMA Biologics: Earnings Outlook
Which way is the ADMA Biologics share price trending?
Why ADMA Biologics Shares Are Rising Today
ADMA Biologics share price hits a one-year high
ADMA Biologics: A Path To Profits Looks Clear
2ADMA : Recap: ADMA Biologics Q1 Earnings
ADMA Biologics Q1 2022 Earnings Preview
See More Headlines
Receive ADMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter.

ADMA Company Calendar

Last Earnings
8/10/2022
Today
10/02/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADMA
Employees
527
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.13
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+69.8%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
4 Analysts

Profitability

Net Income
$-71,650,000.00
Pretax Margin
-66.44%

Debt

Sales & Book Value

Annual Sales
$80.94 million
Book Value
$0.72 per share

Miscellaneous

Free Float
184,772,000
Market Cap
$477.15 million
Optionable
Optionable
Beta
0.92

Key Executives

  • Mr. Adam S. GrossmanMr. Adam S. Grossman (Age 45)
    Co-Founder, Pres, CEO & Director
    Comp: $1.39M
  • Dr. Jerrold B. Grossman D.P.S. (Age 74)
    Ph.D., Co-Founder & Vice Chairman
    Comp: $70.9k
  • Mr. Brian  Lenz CPAMr. Brian Lenz CPA (Age 50)
    CPA, Exec. VP, CFO & GM of ADMA BioCenters
    Comp: $1.02M
  • Ms. Kaitlin Kestenberg
    VP of Compliance, Project Management & Clinical Operations
  • Mr. Michael Goldstein
    Sr. Director & Gen. Counsel
  • Mr. Michael Least
    VP of Sales & Commercial Operations
  • Mr. Drew Pantello
    VP of Marketing & Corp. Devel.
  • Mr. Neal C. Fitzpatrick
    VP of Sales
  • Dr. Gene A. Wetzstein BCOP
    Pharm.D., Exec. Director & Head of Scientific Engagement
  • Ms. Cyndi Tolman
    Sr. VP of Plasma Services













ADMA Stock - Frequently Asked Questions

Should I buy or sell ADMA Biologics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last twelve months. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADMA shares.
View ADMA analyst ratings
or view top-rated stocks.

What is ADMA Biologics' stock price forecast for 2022?

4 brokerages have issued 12-month price targets for ADMA Biologics' stock. Their ADMA share price forecasts range from $3.00 to $5.00. On average, they expect the company's stock price to reach $4.13 in the next twelve months. This suggests a possible upside of 69.8% from the stock's current price.
View analysts price targets for ADMA
or view top-rated stocks among Wall Street analysts.

How have ADMA shares performed in 2022?

ADMA Biologics' stock was trading at $1.41 at the start of the year. Since then, ADMA shares have increased by 72.3% and is now trading at $2.43.
View the best growth stocks for 2022 here
.

When is ADMA Biologics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our ADMA earnings forecast
.

How were ADMA Biologics' earnings last quarter?

ADMA Biologics, Inc. (NASDAQ:ADMA) released its earnings results on Wednesday, August, 10th. The biotechnology company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.02. The biotechnology company earned $33.91 million during the quarter, compared to analysts' expectations of $31.17 million. ADMA Biologics had a negative trailing twelve-month return on equity of 54.78% and a negative net margin of 66.44%. During the same period last year, the company earned ($0.15) EPS.

What guidance has ADMA Biologics issued on next quarter's earnings?

ADMA Biologics issued an update on its FY 2025 earnings guidance on Friday, September, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $300.00M-.

What is Adam S. Grossman's approval rating as ADMA Biologics' CEO?

9 employees have rated ADMA Biologics Chief Executive Officer Adam S. Grossman on Glassdoor.com. Adam S. Grossman has an approval rating of 29% among the company's employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ADMA Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), OrganiGram (OGI), Gran Tierra Energy (GTE), Tilly's (TLYS), Bionano Genomics (BNGO), Novan (NOVN), CNBX Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT).

What is ADMA Biologics' stock symbol?

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

How do I buy shares of ADMA Biologics?

Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ADMA Biologics' stock price today?

One share of ADMA stock can currently be purchased for approximately $2.43.

How much money does ADMA Biologics make?

ADMA Biologics (NASDAQ:ADMA) has a market capitalization of $477.15 million and generates $80.94 million in revenue each year. The biotechnology company earns $-71,650,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis.

How many employees does ADMA Biologics have?

The company employs 527 workers across the globe.

How can I contact ADMA Biologics?

ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The official website for the company is www.admabiologics.com. The biotechnology company can be reached via phone at (201) 478-5552, via email at info@admabio.com, or via fax at 201-478-5553.

This page (NASDAQ:ADMA) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.